Literature DB >> 2007457

Significance of interleukin-6 in patients with inflammatory bowel disease.

K Mitsuyama1, M Sata, K Tanikawa.   

Abstract

The significance of interleukin-6 (IL-6) in patients with inflammatory bowel disease (IBD) was studied by measuring the IL-6 level in serum and colonic tissue by means of an enzyme-linked immunosorbent assay (ELISA), and by examining its localization using an immunohistochemical method. The serum IL-6 level reflected the degree of disease activity, and the extent of affected area, and was also correlated with the serum C-reactive protein (CRP) level. In the colonic mucosa of active IBD, the tissue IL-6 level was markedly elevated, and immunoreactive products of anti-IL-6 antibody were present in infiltrative mononuclear cells in the lamina propria. This indicates that IL-6 production in these cells is enhanced at the site of affected intestine. These results, together with its biological activity and the type of cell producing it, suggest that IL-6 is an available marker to assess disease conditions of IBD and that it might be also involved in the pathophysiology of IBD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007457     DOI: 10.1007/bf02779504

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  35 in total

Review 1.  Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes.

Authors:  P Brandtzaeg; T S Halstensen; K Kett; P Krajci; D Kvale; T O Rognum; H Scott; L M Sollid
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

Review 2.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

3.  Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis.

Authors:  P Brandtzaeg; K Baklien; O Fausa; P S Hoel
Journal:  Gastroenterology       Date:  1974-06       Impact factor: 22.682

Review 4.  Molecular regulation of B lymphocyte response.

Authors:  T Kishimoto; T Hirano
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

5.  Serum levels of interleukin-6 and acute phase responses.

Authors:  M W Nijsten; E R de Groot; H J ten Duis; H J Klasen; C E Hack; L A Aarden
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

6.  Involvement of IL-6 in mesangial proliferative glomerulonephritis.

Authors:  Y Horii; A Muraguchi; M Iwano; T Matsuda; T Hirayama; H Yamada; Y Fujii; K Dohi; H Ishikawa; Y Ohmoto
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

7.  Inflammatory mediators of experimental colitis in rats.

Authors:  D Rachmilewitz; P L Simon; L W Schwartz; D E Griswold; J D Fondacaro; M A Wasserman
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

8.  Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production.

Authors:  T Hirano; T Taga; K Yasukawa; K Nakajima; N Nakano; F Takatsuki; M Shimizu; A Murashima; S Tsunasawa; F Sakiyama
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

9.  Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo.

Authors:  F Takatsuki; A Okano; C Suzuki; R Chieda; Y Takahara; T Hirano; T Kishimoto; J Hamuro; Y Akiyama
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

10.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.

Authors:  M Lotz; F Jirik; P Kabouridis; C Tsoukas; T Hirano; T Kishimoto; D A Carson
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  28 in total

1.  Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.

Authors:  F De Benedetti; T Alonzi; A Moretta; D Lazzaro; P Costa; V Poli; A Martini; G Ciliberto; E Fattori
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.

Authors:  K Mitsuyama; N Tomiyasu; A Suzuki; K Takaki; H Takedatsu; J Masuda; H Yamasaki; S Matsumoto; O Tsuruta; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice.

Authors:  K Mitsuyama; S Matsumoto; S Rose-John; A Suzuki; T Hara; N Tomiyasu; K Handa; O Tsuruta; H Funabashi; J Scheller; A Toyonaga; M Sata
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 4.  Cytokines in inflammatory bowel disease.

Authors:  Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

5.  VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis.

Authors:  Cong Dai; Chang-Qing Zheng; Fan-Ji Meng; Zheng Zhou; Li-Xuan Sang; Min Jiang
Journal:  Mol Cell Biochem       Date:  2012-10-23       Impact factor: 3.396

6.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.

Authors:  H C Reinecker; M Steffen; T Witthoeft; I Pflueger; S Schreiber; R P MacDermott; A Raedler
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.

Authors:  Yan Sun; Lian-Jie Lin; Yan Lin; Li-Xuan Sang; Min Jiang; Chang-Qing Zheng
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.

Authors:  Misato Hashizume; Yasushi Uchiyama; Naoto Horai; Naohisa Tomosugi; Masahiko Mihara
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

9.  Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent.

Authors:  K Kusugami; A Fukatsu; M Tanimoto; M Shinoda; J Haruta; A Kuroiwa; K Ina; K Kanayama; T Ando; T Matsuura
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

Review 10.  NOD-like receptors and inflammation.

Authors:  Rebeccah J Mathews; Michael B Sprakes; Michael F McDermott
Journal:  Arthritis Res Ther       Date:  2008-11-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.